The signing of these pharma deals will benefit AstraZeneca, in way that Pharmaron will provide AstraZeneca with discovery services in the areas of chemistry, drug metabolism and pharmacokinetics , and efficacy screening.
Financial details of these pharma deals were not disclosed.
Dr. Boliang Lou, Pharmaron’s Chairman and CEO, said: “We are honored to be a strategic partner in the drug discovery area with AstraZeneca, a leading pharmaceutical company. This partnership is an important milestone for Pharmaron as we are strengthening our capacity in the area of fully integrated services as a highly competitive and global player.”
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Related reports: Bigpharma Partnering Yearbook 2013
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity